Cancer Vaccines

• Medical researchers are warning that misinformation and vaccine hesitancy could limit the effectiveness of upcoming personalized cancer vaccines. • These vaccines are designed to prevent cancer from returning by training the immune system to recognize specific proteins on a patient's tumor. • Widespread distrust in vaccines may prevent high-risk patients from receiving preventative treatments that could stop a cancer recurrence.

• Moderna and Merck are developing an mRNA cancer vaccine to treat patients with late-stage skin cancer. • The vaccine showed success in clinical trials when used in combination with an immunotherapy drug. • Public distrust and disinformation regarding vaccines could limit the adoption and effectiveness of these new medical treatments.

• Moderna and Merck announced on August 19, 2026, that their personalized mRNA vaccine, intismeran autogene, successfully passed a late-stage clinical trial. • The vaccine was used in combination with the immunotherapy drug Keytruda to effectively reduce the recurrence of melanoma, a form of skin cancer. • This milestone represents a significant breakthrough in oncology, demonstrating the potential for mRNA technology to transform both cancer treatment and prevention.